Stock Research for CARA


Featured Broker: Ally Invest

Get the due diligence for another stock.


CARA Stock Chart & Research Data

The CARA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CARA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CARA Due diligence Resources & Stock Charts

The CARA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CARA Detailed Price Forecast - CNN Money CNN View CARA Detailed Summary - Google Finance
Yahoo View CARA Detailed Summary - Yahoo! Finance Zacks View CARA Stock Research & Analysis -

Stock Analysis

TradeIdeas View CARA Trends & Analysis - Trade-Ideas Barrons View CARA Major Holders - Barrons
NASDAQ View CARA Call Transcripts - NASDAQ Seeking View CARA Breaking News & Analysis - Seeking Alpha
Spotlight View CARA Annual Report - OTC Report View CARA OTC Short Report -
TradeKing View CARA Fundamentals - TradeKing Charts View CARA SEC Filings - Bar Chart
WSJ View Historical Prices for CARA - The WSJ Morningstar View Performance/Total Return for CARA - Morningstar
MarketWatch View the Analyst Estimates for CARA - MarketWatch CNBC View the Earnings History for CARA - CNBC
StockMarketWatch View the CARA Earnings - StockMarketWatch MacroAxis View CARA Buy or Sell Recommendations - MacroAxis
Bullish View the CARA Bullish Patterns - American Bulls Short Pains View CARA Short Pain Metrics -

Social Media Mentions

StockTwits View CARA Stock Mentions - StockTwits PennyStocks View CARA Stock Mentions - PennyStockTweets
Twitter View CARA Stock Mentions - Twitter Invest Hub View CARA Investment Forum News - Investor Hub
Yahoo View CARA Stock Mentions - Yahoo! Message Board Seeking Alpha View CARA Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CARA - Insider Cow View Insider Transactions for CARA - Insider Cow
CNBC View CARA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CARA - OTC Markets
Yahoo View Insider Transactions for CARA - Yahoo! Finance NASDAQ View Institutional Holdings for CARA - NASDAQ

Stock Charts

FinViz View CARA Stock Insight & Charts - StockCharts View CARA Investment Charts -
BarChart View CARA Stock Overview & Charts - BarChart Trading View View CARA User Generated Charts - Trading View

Latest Financial News for CARA

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
Posted on Friday January 28, 2022

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
Posted on Friday January 28, 2022

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
Posted on Tuesday January 25, 2022

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
Posted on Monday January 10, 2022

Study met both primary and secondary endpointsSTAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study (double-

Stock Market & Investing Books

Enter a stock symbol to view the stock details.